The content on this site is intended for healthcare professionals only
Dr Zelenetz presents, at a press conference at ASH 2015, results of a phase III randomised double-blind placebo-controlled study.
Idelalisib plus bendamustine and rituximab is superior to rituximab alone in patients with relapsed/refractory chronic lymphocytic leukaemia.
Read the news story and watch the video interview for more information.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
